Oncologist. Memorial Sloan Kettering Cancer Center. Prostate Cancer Clinical Trials Consortium. The Good News About Cancer Podcast. Author, The Virility Paradox
New York, NY
Joined July 2013
- Tweets3.3K
- Following1.3K
- Followers3.5K
- Likes3.3K
Thank you @cdanicas and the @GuardConsortium team for inviting me to deliver a Keynote talk! Great meeting with so many thoughtful Spanish colleagues and friends!
🎯💯 a Keynote Lecture of the Current status of parpInh in mCSPC @charlesryanmd !! ❤️ @OncoAlert @PCF_Science @ThePCCTC @APCCC_Lugano @GuardConsortium
Heres the sticker! i use the acronym with my patients all the time now! TYI @TylerSbrt !
Well, west coast may be a little different. But I meant everyone knows that eating healthy and exercising are “good.” Absolutely worth reinforcing! And I do, regularly.
I like @charlesryanmd’s approach (and stickers!)
Heres the sticker! i use the acronym with my patients all the time now! TYI @TylerSbrt ! xitter.cf/charlesryanmd/status/2…
Well, west coast may be a little different. But I meant everyone knows that eating healthy and exercising are “good.” Absolutely worth reinforcing! And I do, regularly.
I like @charlesryanmd’s approach (and stickers!)
Charles Ryan retweeted
Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology
asco.org/abstracts-presentat…
The phase 2 ARACOG trial randomized 111 patients with mHSPC, mCRPC, or nmCRPC to darolutamide (DAR) or enzalutamide 💊 (ENZ) and prospectively evaluated cognitive outcomes using the CANTAB platform. At 24 weeks, DAR was associated with significantly less cognitive 🧠 📉 decline than ENZ in the maximally changed cognitive domain (-15.8% vs -36.1%; p=0.009). Cognitive performance appeared stable or improved with DAR, suggesting a learning effect, whereas ENZ showed mild decline.
Notably, all treatment crossovers occurred from ENZ to DAR, primarily due to objective or subjective cognitive deterioration, supporting a more favorable cognitive profile for DAR. #ProstateCancer
@CaPsurvivorship
@CaPsurvivorship @danielkwonmd @deepak_kilari @_StuartBloom @PrafulRavi1 @kvballman @EAntonarakis @charlesryanmd
@OncoAlert
@Silke_Gillessen
@AOmlin
@weoncologists
Charles Ryan retweeted
Exercise is cancer care.
Ask about it.
Document it.
Support it.
Make it possible beyond the clinic.
Our words can move patients toward strength.
@charlesryanmd
@OncoAlert @APCCC_Lugano #APCCC26 @BourlonMaite @nataliagandur @Silke_Gillessen @AOmlin @CaPsurvivorship @NehaVapiwala @piet_ost
Charles Ryan retweeted
#APCCC26 Practical recommendations for physical exercise in patients starting on
long-term systemic therapies #ENERGY framework 💪💪💪@charlesryanmd @OncoAlert @APCCC_Lugano
Charles Ryan retweeted
🏋️ Yay for exercise- Level 1 evidence that it improves survival in cancer! If exercise were a drug it would be FDA approved! Exercise should be considered a vital sign to discuss with all patients and is feasible even in metastatic disease! @charlesryanmd #apccc26
Charles Ryan retweeted
Congrats @aliarafaa and @DrJustinDrake for your elegant work on plasma extracellular vesicle (EV) proteomics in Pluvicto-treated prostate cancer patients. Blood-based detection of PSMA, B7-H3, STEAP1 and Trop2 will help precision therapeutics! @UMNCancer cell.com/cell-reports-medici…
Charles Ryan retweeted
Please check out our CASCARA trial, the first study to use a quadruplet initial systemic regimen for high-volume metastatic prostate cancer. Let’s design a randomized Phase 3 trial to explore this further. @charlesryanmd @UMNCancer aacrjournals.org/clincancerr…
Just launched the first 2026 tranche of #GoodNewsAboutCancer! New podcasts weekly. We start discussing the old...yet brand new...area of Radioligand Therapy w Mike Morris of #MSKCC. listen and follow! podcasts.apple.com/us/podcas…
Wow a Gold Medal for our Podcast #TheGoodNewsAboutCancer!
Proud of this - but what makes me most happy is that the message that we are all making progress against the disease is getting traction!
daveyawards.com/winners-area…
And Episode 1 of Season 2 is out!
podcasts.apple.com/us/podcas…
What could be better #GoodNewsAboutCancer than progress showing that healthy pregnancies with no cancer risk are possible during rx for #BreastCancer?
#AnnePartridge from @DFCI_BreastOnc @DanaFarber discussed the "Positive" Study.
podcasts.apple.com/us/podcas…
We're back! Melanoma is an OG GoodNewsAboutCancer story! This week we talk with one of its Pioneers - Jed Wolchok of @WCM_MeyerCancer @WeillCornell to talk about I/O and #TILS and #CancerVaccines. The past is illuminating and the future is bright! podcasts.apple.com/us/podcas…
My new podcast #TheGoodNewsAboutCancer with the great @CaPsurvivorship from @DanaFarber is on hiatus this week, but a great time to catch up by starting with our pilot episode with Karen Knudsen of @AmericanCancer Here's the link! @mskcc @CitizenRacecar
podcasts.apple.com/us/podcas…
New Uromigos episode alert! Brian, Tom, & Chuck Ryan share insights & passions of the remarkable Felix Fang from the recent ASCO GU Felix Feng Symposium.
Spotify: buff.ly/OkUqGQY]
GU Oncology Now: buff.ly/i2dsYYP
Apple Podcasts: buff.ly/bOdfhgy
@charlesryanmd#ASCOGU #FelixFang#Oncology #GUOncology
Charles Ryan retweeted
Purchase the "Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In" audiobook by 3/28 and save 60%! @charlesryanmd audiobooks.com/promotions/pr…
Thank you @uromigos for putting this out there so that we call can continue to benefit from the wisdom of our friend Felix. We all miss him so much.
Please listen to this special podcast honoring @felixfengmd as @charlesryanmd reflects on his lecture from the ASCO GU Symposium including audio clips from an interview.
spotifycreators-web.app.link…
This week on #GNAC we talk to Pam Munster from @UCSFCancer on her #BRCA story as a carrier, a patient and an innovator. podcasts.apple.com/us/podcas…
Charles Ryan retweeted
Please listen to this special podcast honoring @felixfengmd as @charlesryanmd reflects on his lecture from the ASCO GU Symposium including audio clips from an interview.
spotifycreators-web.app.link…